Dianthus Therapeutics (NASDAQ:DNTH) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note published on Thursday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $135.00 price objective on the stock.

A number of other research analysts have also weighed in on DNTH. Truist Financial raised their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Jefferies Financial Group set a $98.00 target price on Dianthus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 9th. Wedbush increased their price target on Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Finally, Oppenheimer lifted their price objective on Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $117.30.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $77.76 on Thursday. The company’s fifty day moving average price is $56.65 and its 200-day moving average price is $44.60. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $88.02. The company has a market capitalization of $3.46 billion, a PE ratio of -18.97 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. On average, research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In other news, CEO Marino Garcia sold 122,918 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 33,830 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The SEC filing for this sale provides additional information. Insiders have sold a total of 200,430 shares of company stock worth $16,332,702 in the last three months. Insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in Dianthus Therapeutics in the second quarter worth $2,504,000. American Century Companies Inc. lifted its position in Dianthus Therapeutics by 13.2% in the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after buying an additional 6,323 shares during the last quarter. XTX Topco Ltd purchased a new position in Dianthus Therapeutics during the second quarter worth $503,000. Finally, Sio Capital Management LLC boosted its stake in Dianthus Therapeutics by 101.8% during the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after buying an additional 119,073 shares during the period. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.